307 studies found for:    NIAID | Recruiting | Exclude Unknown
Show Display Options
Rank Status Study
21 Recruiting Cause of Unexplained Anaphylaxis
Condition: Anaphylaxis
Intervention:
22 Recruiting Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy
Conditions: Acquired Immune Deficiency Syndrome Virus;   Acquired Immunodeficiency Syndrome Virus;   AIDS Virus;   Human Immunodeficiency Virus;   Human Immunodeficiency Viruses
Intervention:
23 Recruiting Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous Disease
Conditions: Radiofrequency Ablation;   Liver Abscesses -Staphylococcus Infection;   CGD;   Chronic Granulomatous Disease;   RFA
Interventions: Procedure: RFA - Radiofrequency Ablation;   Procedure: Scans - Liver;   Procedure: Liver;   Procedure: Drawn
24 Recruiting Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Conditions: CVID;   Enteropathy;   Chronic Diarrhea;   Maldigestion;   Malabsorption
Intervention: Biological: Ustekinumab
25 Recruiting Parasitic Infections of the Gastrointestinal Tract
Conditions: Amebiasis;   Cryptosporidiosis;   Giardiasis;   Parasitic Disease;   Parasitic Intestinal Disease;   Gastrointestinal Helminth Infections
Intervention:
26 Recruiting Bone Marrow Stromal Cells for Inflammatory Bowel Diseases
Condition: Inflammatory Bowel Disease
Intervention: Other: Bone Marrow Stromal Cell (BMSC) Infusion
27 Recruiting Treatment of Patients With Cysticercosis With Praziquantel or Albendazole
Condition: Cysticercosis
Intervention:
28 Recruiting Immune Regulation in Ulcerative Colitis or Crohn s Disease
Conditions: Crohn's Disease;   Inflammatory Bowel Disease;   Ulcerative Colitis
Intervention:
29 Recruiting Normal Blood, Bone Marrow and Buccal Mucosa Protocol
Condition: Healthy
Intervention:
30 Recruiting Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Interventions: Drug: benralizumab;   Drug: Placebo
31 Recruiting Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies
Condition: Blood Component Removal
Intervention:
32 Recruiting Studies in the Pathogenesis of Systemic Capillary Leak Syndrome
Condition: Systemic Capillary Leak Syndrome
Intervention:
33 Recruiting Testing the AVI-7100 Flu Drug in Healthy Volunteers
Condition: Influenza
Intervention: Drug: AVI-7100 versus placebo
34 Recruiting Natural History of Diseases Associated With Allergic Inflammation: Atopic Dermatitis and Genetic and Congenital Diseases Associated With Atopic Pathways
Condition: Atopic Dermatitis
Intervention:
35 Recruiting Collection of Peripheral Blood and Bone Marrow From Healthy Donors for Use in In Vitro Research
Condition: Healthy
Intervention:
36 Recruiting Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases
Conditions: Occupational Accidents;   Incubation Period, Infectious Disese
Intervention:
37 Recruiting Identification of Viruses Associated With Diseases of Unknown Cause
Condition: Viral Diseases
Intervention:
38 Recruiting Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: Imatinib Mesylate
39 Recruiting Screening Protocol for Genetic Diseases of Mast Cell Homeostasis and Activation
Conditions: Piebaldism;   Idiopathic Anaphylaxis;   Allergy;   Chronic Urticara;   Angioedema
Intervention:
40 Recruiting A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection
Condition: Loiasis
Interventions: Drug: Reslizumab;   Drug: Diethylcarbamazine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years